Search
Valspodar
go.drugbank.com/drugs/DB11869InvestigationalValspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements [A31846]
Categories: Androgen Receptor Inhibitors, P-glycoprotein inducersValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates6-O-benzylguanine
go.drugbank.com/drugs/DB11919Investigational6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed fro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalis an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, P-glycoprotein inhibitorsSJG-136
go.drugbank.com/drugs/DB11965InvestigationalSJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...
Categories: P-glycoprotein substratesBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalElagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Adm...
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, Cytochrome P-450 SubstratesPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates